Certain infectious diseases, such as COVID or the flu, evolve constantly, shapeshifting just enough to outmaneuver our immune ...

Recall germinal centers formed in response to a secondary infection generate a second line of defense, rebuffing memory B ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

Monash University researchers have developed a new technique to boost the effectiveness of both traditional and mRNA-based ...

The introduction of clustered enhancing mutations led to complement activation by anti-capsule antibodies for both K.

Research at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of ...

"Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo" was originally created and published by Pharmaceutical ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Research at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to ...

Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...